15:30am Chair Introduction

Chairperson: Sven Kili, Principal, Sven Kili Consulting

15:35am Presentation: Natural Killer Cell Based Therapies: Lessons Learned

• Cover autologous and allogeneic clinical trials performed
• Discuss strategies around NK cell persistence and efficacy
• Role of donor and patient selection algorithms

Evren Alici, Head of Cell and Gene Therapy Group, Department of Medicine, Karolinska Institutet

15:50am Presentation: From Vision to Reality: Stemmatters’ Role in Supporting Development and Manufacturing of an Innovative Cone Replacement Therapy for Central Vision Loss

Rui A. Sousa, Chief Executive Officer & Chairman, Stemmatters

16:05am Presentation: A Personal Vaccine Platform Technology for Cancer and Infectious Disease

• Dendritic cell vaccines are being manufactured as therapeutic anti-cancer vaccines and as anti-viral vaccines using antigens from self-renewing autologous cancer cells, and immunogenic proteins.  
• Promising data from cancer trials includes safety, induction of immune responses, tumor regressions, and increased progression free and overall survival  
• Promising data from COVID-19 trials demonstrated fewer and lower-grade adverse events, and superior protection to mRNA vaccine technologies.

Hans S. Keirstead, Chairman & Chief Executive Officer, AIVITA Biomedical, Inc.

16:20am Presentation: Okulovision’s Cone Progenitor Cell Therapy for Central Vision Loss 

• Cone progenitor cells (cpc) are a pure population of cells that only regenerate cones after subretinal injection, and mediate improved visual function in rodent models 
• Cpc are highly proliferative, facilitating manufacture to clinical scale 
• Okulovision plans its first clinical trial in patients with cone dystrophies, then advance to patients with macular degeneration.

Marie Csete, Chief Executive Officer, OkuloVision 

16:35pm Closing Panel with Q&A 

With all session participants